Charles River today announced the addition of Dr. Sneha Kumar as the strategic commercial lead of Logica®, the groundbreaking artificial intelligence (AI)-enabled drug discovery platform formed in collaboration with Valo Health. This news follows the announcement of Logica’s first-identified candidate marking a progression-based milestone in an ongoing partnership with Pioneering Medicines.
As Strategic Commercial Lead, Sneha will enable Logica to redefine the future of small molecule drug discovery and development by driving the global commercial expansion of the platform through forging strategic partnerships and forwarding innovation in the ever-evolving pharmaceutical industry.
“I am incredibly excited to be stepping into this role,” Dr. Kumar said. “As AI moves to the forefront of innovation in the pharmaceutical industry, this is a tremendous opportunity to leverage my experience in setting up successful business operations and strategies to bring Logica as a transformative solution into the global AI enabled drug discovery space.”
Dr. Kumar, a senior director of global strategic business development at Charles River, has a decade of business experience in the development and negotiation of collaboration deals across different therapeutic areas. At Charles River, she leveraged her extensive experience in drug discovery and business development to create and manage strategic drug discovery partnerships with biotech and pharmaceutical companies and venture capital.
“Dr. Kumar’s proven track record in developing market strategies makes her the perfect fit for the strategic commercial lead role,” said Julie Frearson, Ph.D., senior vice president and chief scientific officer at Charles River. “Her expertise in driving international growth and creating high-impact partnerships will be instrumental as we expand Logica’s presence in the global commercial market. I’m confident that she will unlock new strategic opportunities that strengthen the Logica platform, allowing for accelerated drug development across the industry.”
Logica’s innovative approach to drug discovery uses AI to seamlessly bridge wet lab experimental techniques with dry lab computational models, creating a more efficient, precise, and accelerated drug development process. This synergy allows for faster, more targeted insights that improve the likelihood of clinical success in discovering novel therapeutics.
Contact our drug discovery experts to learn more about how the power of AI is harnessed to advance the future of drug discovery; Dr. Kumar will also be attending Bio€quity Europe 2025 and is available for in-person dialogue.